Request Demo
Last update 27 Jun 2026
MK-8189
Last update 27 Jun 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Elpipodect, MK 8189, MK8189 |
Target |
Action inhibitors |
Mechanism PDE10A inhibitors(Phosphodiesterase 10A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC19H22N6OS |
InChIKeyWQKPZDLZRFTMTI-CABCVRRESA-N |
CAS Registry1424371-93-6 |
Related
13
Clinical Trials associated with MK-8189NCT06273774
A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Participants With Bipolar I Disorder
The goal of this study is to evaluate the safety and tolerability of elpipodect in participants with stable bipolar I disorder. There was no hypothesis testing in this study.
Start Date08 Apr 2024 |
Sponsor / Collaborator |
NCT05953740
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Long-Acting Injectable of MK-5720 in Participants With Schizophrenia
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending intramuscular doses of MK-5720, and the safety and tolerability of multiple once-daily oral doses of MK-8189, in participants with schizophrenia. The primary study hypothesis is that the administration of MK-5720 is safe and well tolerated.
Start Date15 Sep 2023 |
Sponsor / Collaborator |
NCT05893862
A Double-Blind, Cross-Over Placebo-Controlled and Active-Controlled Trial To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia
The primary purpose of this study to evaluate the effect of a supratherapeutic dose of 80 mg elpipodect on the QT interval corrected for heart rate (QTc interval) and to assess the safety and tolerability of multiple once-daily doses of elpipodect in participants with schizophrenia. The effects of 3 treatment sequences 1) elpipodect (48 mg [Day 1] and 80 mg [Day2]); 2) standard image placebo (Day 1) and moxifloxacin 400 mg (Day 2); and 3) elpipodect placebo (Day 1 and Day 2) were assessed with 5-day washout intervening sequence. Participants received all treatments in a counter-balanced order according to 1 of 6 possible treatment sequences.
The primary hypothesis is that the administration of an 80 mg elpipodect dose on Day 2 does not prolong the QTc interval to a clinically significant degree. Specifically, the true mean difference (elpipodect - placebo) in QTc change from baseline is less than 10 milliseconds (msec).
The primary hypothesis is that the administration of an 80 mg elpipodect dose on Day 2 does not prolong the QTc interval to a clinically significant degree. Specifically, the true mean difference (elpipodect - placebo) in QTc change from baseline is less than 10 milliseconds (msec).
Start Date26 Jun 2023 |
Sponsor / Collaborator |
100 Clinical Results associated with MK-8189
Login to view more data
100 Translational Medicine associated with MK-8189
Login to view more data
100 Patents (Medical) associated with MK-8189
Login to view more data
6
Literatures (Medical) associated with MK-818901 May 2026·JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Phase 2b Trial of the PDE10A Inhibitor MK-8189 in People With an Acute Episode of Schizophrenia
Article
Author: Mukai, Yuki ; Egan, Michael F ; Kent, Justine ; Kost, James ; Snow-Adami, Linda ; Reed, Jessica ; Taylor, Theresa
Background::
PDE10A inhibition represents a potential mechanism for treating schizophrenia. A 12-mg dose of the PDE10A inhibitor MK-8189 showed initial evidence of efficacy for improving schizophrenia symptoms after 4 weeks. We performed a follow-up study evaluating higher MK-8189 doses (16 mg and 24 mg, predicted to produce up to 80% sustained enzyme occupancy) over 6 weeks.
Methods::
Randomized, double-blind, phase 2b study consisting of a 6-week acute treatment period and a 6-week extension (NCT04624243). Participants were diagnosed with schizophrenia and were experiencing active phase symptoms. For the acute treatment period, participants were randomized in a 2:2:2:1:2 ratio to 6 weeks of daily MK-8189 8 mg (dropped after a third of participants had been enrolled), 16 mg, 24 mg, risperidone 6 mg (for assay sensitivity), or placebo. The primary outcome was the change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at 6 weeks.
Results::
The number of treated participants in the acute period was: MK-8189 16 mg, N=132; MK-8189 24 mg, N=132; risperidone 6 mg, N=65; and placebo, N=129. MK-8189 16 mg and 24 mg did not show an improvement versus placebo for change-from-baseline in PANSS total score after 6 weeks [16 mg-placebo difference, −2.8 (95% CI: −8.3,2.6),
P
=0.241; 24 mg-placebo difference, −0.7 (95% CI: −6.3,4.9),
P
=0.784], whereas risperidone did [risperidone-placebo difference, −6.2 (95% CI: −12.9,0.6),
P
=0.040]. Over the 6-week acute period, more participants discontinued treatment due to an adverse event in the MK-8189 24 mg group (25.0%) than in the MK-8189 16 mg (12.9%), risperidone (12.3%) or placebo (12.4%) groups.
Conclusions::
These findings suggest that PDE10A inhibition does not have antipsychotic effects at the doses tested.
01 Aug 2024·SCHIZOPHRENIA RESEARCH
Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial
Article
Author: Mukai, Yuki ; Egan, Michael F ; Voss, Tiffini ; Smith, Sean M ; Lupinacci, Robert ; Snow-Adami, Linda ; Marder, Stephen
BACKGROUND:
PDE10A inhibition represents a potential mechanism for treating schizophrenia. PDE10A inhibitors increase cyclic nucleotides in striatal neurons, thereby mimicking the effects of dopamine receptor D2 antagonists and D1 agonists. We evaluated the PDE10A inhibitor MK-8189 for treating schizophrenia.
METHODS:
Randomized, double-blind, placebo and active-controlled, phase 2a, multicenter, inpatient trial in adults experiencing an acute episode of schizophrenia. Participants were randomized 2:2:1 to once-daily MK-8189 12 mg, placebo, or risperidone 6 mg (active control) for 4-weeks. The primary outcome was change-from-baseline in total score on the Positive and Negative Syndrome Scale (PANSS) at 4 weeks.
RESULTS:
The number of treated participants was 90 for MK-8189, 89 for placebo, and 45 for risperidone. MK-8189 demonstrated a trend towards improvement versus placebo for change-from-baseline in PANSS total score after 4 weeks (difference = -4.7 [95 % CI: -9.8,0.5], P = 0.074). The active control risperidone was superior to placebo on PANNS total score (difference = -7.3 [95 % CI: -14.0,-0.6], P = 0.033), demonstrating assay sensitivity, while MK-8189 and risperidone did not significantly differ (difference = 2.6 [95 % CI: -4.0,9.2], P = 0.440). MK-8189 had a nominally significant effect on PANSS positive subscale score compared to placebo (difference = -2.2 [95 % CI: -3.8,-0.5], P = 0.011). Discontinuation of MK-8189 treatment due to an adverse event was low (<10 %). Extrapyramidal symptoms occurred with MK-8189 but were mostly mild and transient. Compared with placebo, MK-8189 reduced body weight while risperidone increased weight.
CONCLUSIONS:
These findings suggest that PDE10A inhibition may produce antipsychotic effects and associated weight loss and that further trials with PDE10A inhibitors are warranted.
TRIAL REGISTRATION:
Clinicaltrials.gov identifier: NCT03055338.
22 Feb 2024·Journal of medicinal chemistryQ1 · MEDICINE
Fragment-to-Lead Medicinal Chemistry Publications in 2022
Q1 · MEDICINE
Review
Author: de Esch, Iwan J. P. ; Pathuri, Puja ; Jahnke, Wolfgang ; Erlanson, Daniel A. ; Woodhead, Andrew J. ; Holvey, Rhian S.
This Perspective is the eighth in an annual series that summarizes successful fragment-to-lead (F2L) case studies published each year. A tabulated summary of relevant articles published in 2022 is provided, and features such as target class, screening methods, and ligand efficiency are discussed both for the 2022 examples and for the combined examples over the years 2015-2022. In addition, trends and new developments in the field are summarized. In 2022, 18 publications described successful fragment-to-lead studies, including the development of three clinical compounds (MTRX1719, MK-8189, and BI-823911).
5
News (Medical) associated with MK-818930 Sep 2024
Multidisciplinary board members bring expertise in drug discovery, clinical development, computational life science, GPCRs and drug formulationBOSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Superluminal Medicines, Inc., “The Membrane Company” using generative biology, chemistry and machine learning approaches to revolutionize the speed and accuracy of how medicines are created, today announced the formation of its Scientific Advisory Board (SAB). Comprised of renowned experts whose skillsets span drug discovery, computational life science, translational research, GCPRs, clinical trials and commercialization, the newly formed SAB has a deep understanding of Superluminal Medicines and its strategic priorities and will play a crucial role in advising the Company as it progresses its lead program into clinical development and increases the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets. “The members of our new Scientific Advisory Board are world-renowned experts in their fields who have pushed the boundaries of science, established new areas of research and have brought new therapeutics to market,” said Cony D'Cruz, CEO of Superluminal Medicines. “I can think of no better set of advisors to help Superluminal Medicines take our lead program into clinical development, advance six small molecule programs and build our discovery platform to quickly and efficiently generate therapeutics for any membrane drug target.” Inaugural members of Superluminal Medicine’s Scientific Advisory Board include: Morris J. Birnbaum MD, PhD, SAB Chairman, is a physician-scientist who has led research teams in academic and pharmaceutical settings, investigating fundamental problems in metabolic regulation and their relevance to chronic disease. Dr. Birnbaum was Senior Vice President and Chief Scientific Officer, at Pfizer Inc., initially of the Cardiometabolic and later the Internal Medicine Research Unit, where he was responsible for the discovery and early clinical development of drugs designed to treat metabolic diseases. Under his leadership, Pfizer brought seven novel potential medicines into clinical development. Dr. Birnbaum has held faculty positions at Harvard Medical School, the Perelman School of Medicine at the University of Pennsylvania, and the Howard Hughes Medical Institute. Dr. Birnbaum received his AB, PhD and MD from Brown University and completed an Internal Medicine residency at Barnes Hospital at Washington University in St. Louis, followed by postdoctoral training at the University of California, San Francisco, and Sloan-Kettering Institute in New York. John Griffin, PhD, is an entrepreneur and advisor to science-driven organizations. With more than 30 years of R&D leadership experience, he is the Co-Founder and former Chief Scientific Officer of Theravance, Inc. Dr. Griffin was Chief Scientific Officer of Numerate, a startup that sought to overcome major challenges in drug discovery by applying novel machine-learning algorithms to drug design at cloud scale which was acquired by Valo Health. After the acquisition, he was Vice President at Valo Health—a technology company focused on utilizing large-scale data and AI-driven computation to discover and develop therapeutics. Dr. Griffin was also an Assistant Professor of Chemistry at Stanford University, has authored 40 publications and is co-inventor of 29 patents. He received his BS in Chemistry from Hope College, a PhD in Chemistry from the California Institute of Technology and was a National Science Foundation Postdoctoral Fellow at Harvard Medical School. Carrie Haskell-Luevano, PhD, conducts research focused on GPCRs, the neuroendocrine regulation of pain (opioid receptors), food intake and energy homeostasis (melanocortin receptors). She is the Philip S. Portoghese Endowed Chair in Chemical Neuroscience at the University of Minnesota’s Department of Medicinal Chemistry. The Haskell-Luevano laboratory uses a variety of multidisciplinary techniques and research approaches including peptide, small molecule and combinatorial chemistry synthesis; cell-based assays; chemical biology; neuromolecular pharmacology; developing knock-out mice and neuroscience. The Haskell Luevano laboratory has published over 130 peer-reviewed manuscripts, reviews, book chapters and conference proceedings. Dr. Haskell-Luevano completed her postdoctoral studies and started an independent research program at the University of Florida Department of Medicinal Chemistry, where she was promoted through the ranks of Assistant, Associate, and Full Professor. Dr. Haskell-Luevano received her BS degree in Chemistry from the California State University of Fresno and her PhD in Chemistry at the University of Arizona. Terrence Kenakin, PhD, is a leader in the use of pharmacologic tools and concepts to characterize the activity of molecules in biological systems using quantified molecular properties so that their activity can be predicted in therapeutic and other systems. Currently, Dr. Kenakin is Professor of Pharmacology at the University of North Carolina School of Medicine in Chapel Hill, where he optimizes the design of drug activity assay systems, discovery and testing of allosteric molecules for therapeutic application and quantitative modeling of drug effects. He joined Burroughs-Wellcome as an associate scientist following a postdoctoral fellowship at University College London, UK . Dr. Kenakin worked in drug discovery for 25 years at Glaxo, Inc., Glaxo Wellcome and GlaxoSmithKline’s Research and Development laboratories. He has authored numerous articles and 10 books on Pharmacology. Dr. Kenakin received his BSc in Organic Chemistry and PhD in Pharmacology from the University of Alberta in Canada. Georgia McGaughey, PhD, is a veteran scientific leader with more than 30 years of corporate experience in drug discovery and digital transformation earned at Pfizer, Merck and Vertex Pharmaceuticals. In 2024, she retired from Vertex Pharmaceuticals where she was Vice President of the global Data and Computational Sciences (DCS) group and a member of the Research Leadership Team, which is responsible for the scientific strategy and direction for the entire Vertex drug discovery portfolio. Under her leadership, the DCS group was responsible for leveraging data and advanced analytics with impact from research to FDA approval and played a central role in the approval of CASGEVY®, a gene-editing CRISPR therapy. Dr. McGaughey spent 13 years at Merck in a variety of roles in infectious diseases, CNS and other therapeutic areas, contributing directly to Belsomra®, Filorexant, MK-8189 and MK-8193, a PET-tracer used to measure target engagement for PDE10. Upon her departure from Vertex, Dr. McGaughey founded Trilligant to continue lending her expertise in digital transformation for a wide variety of businesses from sports analytics to drug discovery. Dr. McGaughey completed her PhD studies at the University of Georgia and has published over 100 peer-reviewed scientific publications and contributed to numerous patents. Sandeep Menon, MD, PhD, MPH, MS, is the Chief Development Officer at Alnylam Pharmaceuticals, where he leads a multifunctional global team and oversees end-to-end development. Before, Dr. Menon was Senior Vice President and head of Early Clinical Development at Pfizer. He oversaw Pfizer’s early clinical pipeline of assets from IND through Phase 2b across all therapeutic areas, playing a critical leadership role in increasing Pfizer’s R&D productivity resulting in a Phase II success rate of over 50%. In 2021, his team co-led the early clinical development of Paxlovid, which went from first-in-human to emergency use authorization in nine months. He also served as Chief Scientific Officer for AI and Digital Sciences, overseeing the cutting-edge Pfizer Innovation and Research Lab (PfIRE Lab), responsible for using state-of-the-art technology to develop meaningful novel quantitative digital endpoints through dynamic and remote monitoring of human behaviors. Prior to Pfizer, Dr. Menon was at Biogen where he worked on Tecfidera and Tysabri; prior to that he was a Research fellow at Harvard Clinical Research Institute. Dr. Menon received his medical degree from Karnataka University, India, his Master’s in Public Health and PhD in Biostatistics at Boston University and his MS in Translational Pharmacology from Ohio State University. He has published over 70 peer-reviewed scientific publications and book chapters and co-authored / co-edited 9 books. About Superluminal Medicines Inc. Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. The company’s platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. The company’s proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets. Based in Boston, the company is backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP. For more, visit www.superluminalrx.com. Media ContactJanine McCargo6 Degreesjmccargo@6degreespr.com
AcquisitionExecutive ChangePhase 2
16 May 2023
The psychosis in Parkinson's and Alzheimer's disease market size shall grow during the forecast period (2023–2032). This increase will be due to rising disease awareness and improving diagnosis, besides the launch of emerging therapies by key companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, and others.
LAS VEGAS, May 16, 2023 /PRNewswire/ -- DelveInsight's
Psychosis in Parkinson's and Alzheimer's Disease Market Insights report includes a comprehensive understanding of current treatment practices, psychosis in Parkinson's and Alzheimer's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Psychosis in Parkinson's and Alzheimer's Disease Market Report
As per DelveInsight analysis, the psychosis in Parkinson's and Alzheimer's disease market size in the 7MM was approximately
USD 1.2 billion in 2022.
According to the assessment done by DelveInsight, the estimated total diagnosed prevalent psychosis in Parkinson's and Alzheimer's disease cases in the 7MM were approximately
6.7 million in 2022.
Leading psychosis in Parkinson's and Alzheimer's disease companies such as
Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, and others are developing novel psychosis in Parkinson's and Alzheimer's disease drugs that can be available in the psychosis in Parkinson's and Alzheimer's disease market in the coming years.
The promising psychosis in Parkinson's and Alzheimer's disease therapies in the pipeline include
Ulotaront (SEP-363856), KarXT (xanomeline-trospium), FANAPT (iloperidone), Masupiridine (SUVN-502), ENT-01, ITI-1284, MK-8189
, and others.
Discover which therapies are expected to grab the major psychosis in Parkinson's and Alzheimer's disease market share @
Psychosis in Parkinson's and Alzheimer's Disease Market Report
Psychosis in Parkinson's and Alzheimer's Disease Overview
Psychosis is a group of symptoms that affect the mind and indicate a loss of contact with reality. Individuals' ideas and perceptions are altered during a psychotic episode, making it difficult to distinguish between what is genuine and what is not. In Parkinson's disease and Alzheimer's disease, both exogenous and endogenous factors contribute to the development of psychosis. Old age, sleep difficulties, long-term neurodegenerative conditions, depression, cognitive impairment, and vision abnormalities are all risk factors for the disease.
Parkinson's disease psychosis (PDP) is a prevalent occurrence in Parkinson's disease patients that is associated with significant morbidity and mortality. It is caused by anomalies in dopamine, serotonin, and glutamate neurotransmission induced by Lewy body deposition in the brain. Alzheimer's disease psychosis (ADP), which is common in Alzheimer's disease patients, is caused by increased excitatory neuron sensitivity and post-transcriptional mechanisms that alter synaptic protein in the brain. Due to the complexity of the aetiologies and physiological hypotheses, many diagnostic techniques, including neuroimaging, neurophysiological, genotypic, and serologic examinations, are used to diagnose psychosis in Parkinson's and Alzheimer's disease patients.
Psychosis in Parkinson's and Alzheimer's Disease Epidemiology Segmentation
DelveInsight estimates that there were approximately
6.7 million diagnosed prevalent cases of psychosis in Parkinson's and Alzheimer's disease in the 7MM in 2022.
Among the 7MM, the US contributed to the largest diagnosed prevalent psychosis population in Parkinson's and Alzheimer's disease, acquiring
~34% in 2022. In contrast, the UK accounted for the least, with approximately
4% of the total population share in 2022.
The psychosis in Parkinson's and Alzheimer's disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total diagnosed prevalent cases of Parkinson's and Alzheimer's disease
Age-specific cases of Parkinson's and Alzheimer's disease
Gender-specific cases of Parkinson's and Alzheimer's disease
Total diagnosed prevalent cases of Psychosis in Parkinson's and Alzheimer's disease
Psychosis in Parkinson's and Alzheimer's Disease Treatment Market
The current treatment of psychosis in Parkinson's and Alzheimer's disease includes both nonpharmacological and pharmacological treatments. The major goal of psychosis in Parkinson's and Alzheimer's disease treatment is to lessen the frequency and severity of psychotic symptoms while causing little worsening of motor symptoms. The use of conventional and atypical antipsychotics (e.g., aripiprazole, clozapine, quetiapine, and others) is the first-line treatment. However, atypical antipsychotics are frequently chosen in the initial therapy, which minimizes the likelihood of further worsening in patients. Aside from
antipsychotics,
5-HT3 receptor antagonists, acetylcholinesterase inhibitors (donepezil, rivastigmine), and various antidepressants are utilized. While cognitive behavioral therapy (CBT), reasoning, and rehabilitation are used to reduce behavioral and psychological symptoms of dementia (BPSD), anxiety, psychosis, agitation, aggression, sleep difficulties, and other symptoms linked with psychosis in Parkinson's and Alzheimer's disease.
The US FDA has approved
ACADIA's NUPLAZID (pimavanserin), a receptor antagonist (5-HT2A, 5-HT2C), for the treatment of hallucination and delusion associated with psychosis in Parkinson's disease patients. It is the only approved therapy available in the US. Recent trials also suggest that the medicine is helpful in Alzheimer's disease patients with more severe psychosis. At the same time, more long-term studies are needed to define better the efficacy and long-term safety profile of pimavanserin for treating psychosis in Alzheimer's disease. Though the expensive cost of pimavanserin certainly restricts its use, the findings in Parkinson's disease psychosis patients and evidence from Alzheimer's disease trials are convincing.
There are currently no approved medicines for Alzheimer's disease psychosis patients; the major treatment is antipsychotics. Off-label therapies that are routinely utilized include
quetiapine, clozapine, risperidone, aripiprazole, citalopram, and escitalopram. Aripiprazole has been shown in clinical tests to be effective and safe. In contrast, citalopram has been shown to be useful in lowering agitation and the severity of hallucinations and delusions in Alzheimer's disease psychosis patients.
To know more about psychosis in Parkinson's and Alzheimer's disease treatment guidelines, visit @
Psychosis in Parkinson's and Alzheimer's Disease Management
Psychosis in Parkinson's and Alzheimer's Disease Pipeline Therapies and Key Companies
Ulotaront (SEP-363856): Sunovion Pharmaceuticals
KarXT (xanomeline-trospium): Karuna Therapeutics
FANAPT (iloperidone): Vanda Pharmaceuticals
Masupiridine (SUVN-502): Suven Life Sciences
ENT-01: Enterin
ITI-1284: Intra-Cellular Therapies
MK-8189: Merck Sharp & Dohme
Learn more about the FDA-approved drugs for psychosis in Parkinson's and Alzheimer's disease @
Drugs for
Psychosis in Parkinson's and Alzheimer's Disease Treatment
Psychosis in Parkinson's and Alzheimer's Disease Market Dynamics
The psychosis in Parkinson's and Alzheimer's disease market dynamics are anticipated to change in the coming years due to
increasing awareness and improved diagnosis. Increased awareness and a better understanding of disease pathogenesis have improved diagnosis and treatment. Moreover, the recent
FDA approval of NUPLAZID, the first approved therapy for treating hallucinations and delusions associated with Parkinson's disease psychosis, suggests a positive shift in the psychosis in Parkinson's and Alzheimer's disease market. Furthermore, pharma companies have an opportunity to develop
therapies with enhanced safety and tolerability profiles, effectively lowering symptoms and preventing the recurrence of psychosis in Parkinson's and Alzheimer's disease. In addition, the
advancement of biomarkers for cognitive impairment enables exact diagnosis and individualized therapy.
However, several factors are impeding the growth of psychosis in the Parkinson's and Alzheimer's disease market. Psychosis in Parkinson's disease and Alzheimer's disease is related to
low quality of life, higher healthcare resource utilization, and a significant
economic burden.
NUPLAZID and the other atypical
antipsychotics recommended for treatment include black box warnings and adverse effects. Moreover, a
lack of a medication development pipeline, the
ongoing use of antipsychotics despite the hazards, and a lack of specialized nonpharmacological interventions may cause a dip in the growth of psychosis in the Parkinson's and Alzheimer's disease market. Furthermore, there is a
high attrition rate when drug development proceeds from first-in-human trials to pivotal registration studies due to a lack of efficacy. Hence all these factors may hamper the psychosis in Parkinson's and Alzheimer's disease market growth in the coming years.
Scope of the
Psychosis in Parkinson's and Alzheimer's Disease
Market Report
Therapeutic Assessment: Psychosis in Parkinson's and Alzheimer's Disease current marketed and emerging therapies
Psychosis in Parkinson's and Alzheimer's Disease
Market Dynamics: Attribute Analysis of Emerging Psychosis in Parkinson's and Alzheimer's Disease Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Psychosis in Parkinson's and Alzheimer's Disease Market Access and Reimbursement
Discover more about psychosis in Parkinson's and Alzheimer's disease drugs in development @
Psychosis in Parkinson's and Alzheimer's Disease Clinical Trials
Table of Contents
Related Reports
Parkinson's Disease Psychosis Pipeline
Parkinson's Disease Psychosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease psychosis companies, including
Vanda Pharmaceuticals, Sumitomo Pharma, among others.
Psychosis Market
Psychosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis companies, including
Teva Pharmaceutical Industries Ltd., Amgen Inc., Pfizer Inc., Novartis International AG., Merck & Co. Inc., Sanofi S.A., among others.
Parkinson's Disease Psychosis Market
Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease psychosis companies, including
Vanda Pharmaceuticals, Sumitomo Pharma, among others.
Alzheimer's Disease Market
Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including
AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
Drug Approval
20 Dec 2022
DUBLIN--(
BUSINESS WIRE
)--The
"Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)"
report has been added to
ResearchAndMarkets.com's
offering.
Alzheimer's disease Therapeutics Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials.
The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease.
Alzheimer's prevalence is rising rapidly and despite decades of research, the disease remains incurable. The majority of therapeutics target symptom reduction and slowing the progression of the disease. The Food and Drug Administration (FDA) approved aducanumab (Aduhelm) for the treatment of certain cases of Alzheimer's disease in June 2021 and this is the first drug approved for Alzheimer's disease in decades.
Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario.
Scope of the Report
The report analyses the Alzheimer's Disease Therapeutics in Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others).
The report analyses the Alzheimer's disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other).
The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical).
The report analyses the Pain Management Drugs Market by Availability (Over the Counter (OTC), Prescription).
The Alzheimer's Disease Therapeutics Pipeline Analysis has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The Global Pain Management Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The key insights of the report have been presented through the leading company shares.
Also, the major, trends, drivers and challenges as well as Unmet Needs of the industry has been analysed in the report.
The companies analysed in the report include Eli-Lily & Co , Elsal Co., Ltd., BioVie, Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S, Novartis, Cognition Therapeutics, Merck Sharp & Dohme LLC, Biogen.
Key Target Audience
Alzheimer's Disease Therapeutics Companies
End Users (Hospitals and clinics)
Research and Development (R&D) Organizations
Government Bodies & Regulating Authorities
Investment Banks and Equity Firms
Key Topics Covered:
1. Introduction
1.1 Alzheimer's Disease Therapeutics Overview
1.2 Scope of Research
2. Executive Summary
2.1 Market Dashboard
2.2 Regional Insights
2.3 Market Ecosystem Factors
3. Research Methodology
3.1 Data Collection Process
3.2 Market Size Calculation-Top-to-Bottom
4. Macro Economic Indicator Outlook
4.1 Global, Region wise GDP Growth
4.2 Global Medical Spending
4.3 Current Healthcare Expenditure
4.4 Pharmaceutical Spending/capita
5. Competitive Positioning
5.1 Companies' Product Positioning
5.2 Competitive positioning
5.2.1 Eli-Lily & Co
5.2.2 Elsal Co., Ltd.
5.2.3 BioVie
5.2.4 Johnson & Johnson
5.2.5 Otsuka Pharmaceutical Co., Ltd.
5.2.6 H. Lundbeck A/S
5.2.7 Novartis
5.2.8 Cognition Therapeutics
5.2.9 Merck Sharp & Dohme LLC
5.2.10 Biogen
6. Alzheimer's disease background
6.1 AD Fact Sheet
6.2 Epidemiology
6.3 Causes and Risk Factors
6.4 Diagnosis and Assessment
6.5 Unmet Needs
7. Therapeutics in Pipeline
7.1 Pipeline Scenario
7.2 Alzheimer's Therapeutics Comparative Review
8. Pipeline Analysis
9. Phase I therapeutics Overview
9.1 LY3372993
9.1.1 Drug Description
9.1.2 Outcomes
9.2 Lu AF87908
9.3 anle138b
9.4 ASN51
9.5 CMS121
9.6 IBC-Ab002
9.7 LX1001
9.8 MK-2214
9.9 MK-8189
9.10 ACU193
9.11 NIO752
9.12 ALN-APP
9.13 TB006
9.14 SNK01
9.15 Pepinemab
9.16 GB-5001
9.17 AC-1202
9.18 SHR-1707
9.19 BEY2153
9.20 JNJ-40346527
9.21 APNmAb005
9.22 NPT 2042
9.23 ALZ-101
10. Phase I/II therapeutics Overview
10.1 Posiphen
10.1.1 Drug Description
10.1.2 Outcomes
10.1.3 Collaborators
10.2 PrimeProT/ PrimeMSKT
10.3 TB006
10.4 RO7126209
10.5 DNL593
10.6 BIIB080
10.7 E2814
10.8 Tdap
10.9 ACI-35.030/ JACI-35.054
10.10 ACI-24.060
10.11 IVL3003
11. Phase II therapeutics Overview
11.1 Lecanemab
11.1.1 Drug Description
11.1.2 Outcomes
11.1.3 Collaborators
11.2 Lomecel-B
11.3 AL002
11.4 AL001
11.5 CT1812 (Elaya)
11.6 APH-1105
11.7 ATH-1017
11.8 T-817MA
11.9 Montelukast buccal film
11.10 ABBV-916
11.11 Bepranemab
11.12 TB006
11.13 LY3372689
11.14 MW150
11.15 EX039
11.16 JNJ-42847922
11.17 REM0046127
11.18 Bryostatin 1
11.19 NanoLithium NP03
11.20 AstroStem
11.21 Gantenerumab
11.22 Semorinemab
11.23 Obicetrapib
11.24 ALZ-801
11.25 CY6463
11.26 Crenezumab
11.27 T3D-959
11.28 PMZ-1620
11.29 GV1001
11.30 ACZ885
11.31 PQ912
11.32 APH-1105
11.33 SLS-005
11.34 Flos gossypii flavonoids
11.35 Human Mesenchymal Stem cells (MSCs)
11.36 JNJ-63733657
11.37 IGC-AD1
11.38 TW001
11.39 ABvac40
12. Phase II/III therapeutics Overview
12.1 Tricaprilin
12.1.1 Drug Description
12.1.2 Outcomes
12.2 ANAVEX2-73
12.3 Piromelatine
12.4 AGB101
13. Phase III therapeutics Overview
13.1 Simufilam
13.1.1 Drug Description
13.1.2 Outcomes
13.1.3 Collaborators
13.2 ATH-1017
13.3 Lecanemab
13.4 Nilotinib BE
13.5 Brexpiprazole
13.6 Masitinib
13.7 Remternetug
13.8 Donanemab
13.9 NE3107
13.10 Gantenerumab
13.11 GV-971
13.12 Aducanumab
13.13 TRx0237
13.14 Semagludtide
13.15 BPDO-1603
13.16 AR1001
13.17 KarXT
13.18 AXS-05
14. Phase IV therapeutics Overview
14.1 Choline Alfoscerate
14.1.1 Drug Description
14.1.2 Outcomes
14.2 Ebicomb
14.3 Rivastigmine
14.4 GV-971
15. Preclinical Phase therapeutics Overview
15.1 PMN310
15.1.1 Drug Description
15.1.2 Outcomes
15.1.3 Collaborators
15.2 PRX123
16. Pipeline analysis, By molecule type
16.1 Alzheimer's Therapeutics Comparative Review, by Molecule type
17. Pipeline analysis, By Route of Administration
17.1 Alzheimer's Therapeutics Comparative Review, By Route of Administration
For more information about this report visit
https://www.researchandmarkets.com/r/wcw7f7
Drug ApprovalPhase 2Phase 1
100 Deals associated with MK-8189
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute schizophrenia | Phase 2 | United States | 08 Mar 2017 | |
| Bipolar I disorder | Phase 1 | United States | 08 Apr 2024 | |
| Aggression | Phase 1 | United States | 01 Jul 2022 | |
| Agitation | Phase 1 | United States | 01 Jul 2022 | |
| Alzheimer Disease | Phase 1 | United States | 01 Jul 2022 | |
| Schizophrenia | Phase 1 | - | 05 Aug 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Phase 1 | 34 | Placebo (Panel A: Placebo) | gusrgpqarc = gpwvgapepz zbzfqckgtf (oqdadgztor, xgtbkpjopw - jgftwstwmz) View more | - | 17 Aug 2025 | ||
Placebo (Panel C: Placebo) | gusrgpqarc = uogaopirij zbzfqckgtf (oqdadgztor, jnefglumbf - cgetxcstbu) View more | ||||||
Phase 1 | 107 | (MK-8189 48 mg Day 1) | stxwfnmbjk(vnanlozxcs) = ognzvmvrti xhuksjyfzo (ujywiqimaz, zbqpaxtvke - tgmfyseqos) View more | - | 22 Apr 2025 | ||
Placebo (Placebo Day 1) | stxwfnmbjk(vnanlozxcs) = cxcgxtysxa xhuksjyfzo (ujywiqimaz, uazwtxpgdu - fapbjqotlj) View more | ||||||
Phase 1 | 29 | Placebo | usyccarplc = mwuukxtprz sbcbmwphhx (vwkfdufusl, djwbrhjtft - ojqkceiosd) View more | - | 25 Sep 2024 | ||
Phase 1 | 53 | (Panel A MK-8189 48 mg) | lnsmyqqqhd = udnuipwrnp yqekjezyea (oiditeooct, uhddxwyxbd - iounulycvt) View more | - | 25 Jul 2024 | ||
(Panel A MK-8189 60mg) | lnsmyqqqhd = vegylniuth yqekjezyea (oiditeooct, sqbffsapmf - wimfrhrsrw) View more | ||||||
Phase 1 | 14 | (Moderate Hepatic Impairment Participants) | hhmxvocawa(qyourxxhnt) = schvwsfeji ozpcrkxiyw (pjxszggfau, weytldjmld - nicuuuddnh) View more | - | 06 Oct 2023 | ||
(Healthy Participants) | hhmxvocawa(qyourxxhnt) = pedlxmlbgb ozpcrkxiyw (pjxszggfau, tfczahfbde - rigxxjpxlp) View more | ||||||
Phase 2 | 224 | risperidone+Placebo matching MK-8189 (Risperidone) | tfikvervyl(prvsuizghs) = dbsxkafgou axryvwyzwl (tgwbjvvuyt, mesulkkxmj - xkneoantbg) View more | - | 26 Dec 2018 | ||
Placebo matching risperidone (Placebo) | tfikvervyl(prvsuizghs) = nhidwrxwws axryvwyzwl (tgwbjvvuyt, nykrvjbklw - lrgrfsxmyv) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free